---
title: "Alnylam Pharmaceuticals reports mixed Q4 results; initiates FY25 outlook"
date: "2025-02-13 16:04:08"
summary: "Alnylam Pharmaceuticals press release (NASDAQ:ALNY): Q4 GAAP EPS of -$0.65 misses by $0.06. Revenue of $593.17M (+34.9% Y/Y) beats by $12.55M. 2025 Financial Guidance Our full-year 2025 financial guidance is summarized below: Total TTR net product revenues (ONPATTRO, AMVUTTRA)1 $1,600 million - $1,725 million Total Rare net product revenues (GIVLAARI,..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Alnylam Pharmaceuticals [press release](https://seekingalpha.com/pr/20001411-alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and) (NASDAQ:[ALNY](https://seekingalpha.com/symbol/ALNY "Alnylam Pharmaceuticals, Inc.")): Q4 GAAP EPS of -$0.65  misses by $0.06.
* Revenue of $593.17M (+34.9% Y/Y)  beats by $12.55M.
* **2025 Financial Guidance**
  
  **Our full-year 2025 financial guidance is summarized below:**
  
  | Total TTR net product revenues (ONPATTRO, AMVUTTRA)1 | $1,600 million - $1,725 million |
  | --- | --- |
  | Total Rare net product revenues (GIVLAARI, OXLUMO) | $450 million - $525 million |
  | Total net product revenues | $2,050 million - $2,250 million **vs. $2.68B consensus** |
  | Net product revenues growth vs. 2024 at currency exchange rates as of December 31, 20242 | 25% - 37% |
  | Net product revenues growth vs. 2024 at constant exchange rates3 | 26% - 39% |
  | Net revenues from collaborations and royalties4 | $650 million - $750 million |
  | Non-GAAP R&D and SG&A expenses5 | $2,100 million - $2,200 million |
  | Non-GAAP Operating income5 | Achieve profitability |

[seekalpha](https://seekingalpha.com/news/4407628-alnylam-pharmaceuticals-reports-mixed-q4-results-initiates-fy25-outlook)
